DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rifater (Rifampin / Isoniazid / Pyrazinamide) - Published Studies

 
 



Rifater Related Published Studies

Well-designed clinical trials related to Rifater (Rifampin / Isoniazid / Pyrazinamide)

Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. [2003.12]

Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. [2002.11]

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. [2000.03.15]

Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. [1999.02]

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. [1999.01]

[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy] [1998.11]

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. [1997.12]

A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. [1995.06]

Well-designed clinical trials possibly related to Rifater (Rifampin / Isoniazid / Pyrazinamide)

Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens. [2005.11]

Short-course chemotherapy for paediatric respiratory tuberculosis: 5-year report. [2005.06]

Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? [2005.03]

A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. [2005.02]

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. [2005.01.14]

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. [2004.10.02]

[Treatment of latent tuberculosis among homeless population. Comparison between wo therapeutic approaches] [2004.01.24]

Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol. [2003.10]

Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. [2003.08]

[Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy] [2003.06]

Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. [2002.10]

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. [2002.01]

Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. [2001.11.09]

The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations. [2001.08]

Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. [2001.01.26]

A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. [2000.06]

Twice weekly vs. daily chemotherapy for childhood tuberculosis. [2000.05]

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. [2000.03]

The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. [1999.11]

Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. [1999.08]

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. [1999.05.29]

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. [1998.12.24]

Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. [1998.11]

Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. [1998.10]

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. [1998.06]

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). [1998.05]

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. [1998.03.14]

Prospective study of corticosteroid as an adjunct in the treatment of endobronchial tuberculosis in adults. [1997.12]

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. [1997.09.18]

Randomised controlled clinical trial of short course chemotherapy in abdominal tuberculosis: a five-year report. [1997.02]

Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. [1997.02]

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. [1996.11]

Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. [1996.06]

Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration. [1996.06]

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. [1996.05]

Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels. [1996.04]

[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiotherapie de la Tuberculose] [1995.10]

A controlled clinical trial of short-course chemotherapy for tuberculoma of the brain. [1995.08]

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. [1995.06]

Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. [1995.04]

Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters. [1995]

Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin. [1995]

Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. [1994.11.12]

Clinically significant drug interactions with antituberculosis agents. [1994.10]

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. [1994.10]

[Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project] [1994.10]

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. [1993.12]

Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. [1993.10]

[Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide] [1993.06.26]

Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. [1993]

Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. [1990.12]

A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis. [1990.11]

Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet. [1990.04.21]

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. [1990.03.15]

[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment] [1990]

Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. [1989.11.18]

[Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis] [1989]

Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions. [1988.12]

Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. [1988.03]

Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report. [1988.03]

Other research related to Rifater (Rifampin / Isoniazid / Pyrazinamide)

[Mycobacterium ulcerans infection treated by Rifater, pyrazynamide, Myambutol, and surgery: a case report with a 6-year follow-up] [2008.03]

National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. [2005.10.15]

A case of pseudomembranous colitis associated with rifampin. [2004.12]

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. [2004.11]

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? [2004.08.15]

Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. [2004.08.15]

Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. [2004.06]

Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. [2004.05]

Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. [2004.03]

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. [2004.02.01]

Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. [2003.09]

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. [2003.03.15]

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. [2003.01]

Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. [2002.11]

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. [2002.10.15]

Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. [2001.03]

Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model. [2000.11]

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. [1996.10]

Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. [1996.03]

Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. [1996.02]

Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. [1994.06]

Rifampin-resistant Mycobacterium kansasii. [1994.05]

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. [1992.03]

Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children. [1991.11]

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. [1989.11]

Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. [1988.10]

Other possibly related research studies

[Tuberculous otitis media. Report of 3 cases] [2003]

[Pulmonary tuberculosis presenting as tubercular lupus] [2002.09]

[The use of antitubercular drugs in primary care] [1999.03.15]

[Oral desensitization to antitubercular agents] [1997]

[Tuberculosis therapy in canton Zurich 1991-1993: what are the causes for recurrence and therapy failure?] [1996.11.30]

Multiple small bowel perforations in a patient on treatment of tuberculosis. [1996.10]

Fixed-dose combinations of antituberculous medications to prevent drug resistance. [1995.06.15]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017